Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our customタンパク質 services!
カスタムサービスについてのお問い合わせはこちら >>
Limited Edition Golden Llama is here! Check out how you can get one. 
Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free! Offering SPR-BLI Services - Proteins provided for free!
Thank you for choosing ACROBiosystems. Would you rate our product and service？ Thank you for choosing ACROBiosystems. Would you rate our product and service？
Here come GMP Grade Cytokines！Free Sample is available！ Here come GMP Grade Cytokines！Free Sample is available！
| Project Name | Project Stage | Molecule Type | Host Species | Therapeutic Area | Indications |
| BCMA VHH - 01 | Lead | Hematological Malignancy | Multiple myeloma |
| Project Name | Modality | Therapeutic Area | Indications | Stage | Right Available |
| CS1+BCMA CAR-T | Cell therapy | Oncology/Cancer | MM | IND | Global（except Europe/Canada） |
5e5 of anti-BCMA CAR-293 cells were stained with 100 μL of 1 μg/mL of AF488-Labeled Human BCMA, His Tag (Cat. No. BCA-HA2H8) and negative control protein respectively (Fig. C and B), and non-transfected 293 cells were used as a control (Fig. A). AF488 signal was used to evaluate the binding activity (QC tested).
Anti-BCMA Neutralizing Antibody, Mouse IgG1 (Clone: AM43, Cat. No. BCA-M43) captured on CM5 chip via anti-mouse antibodies surface can bind Human BCMA, His Tag (Cat. No. BCA-H522y) with an affinity constant of 0.388 nM as determined in a SPR assay (Biacore T200) (Routinely tested).
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Idecabtagene vicleucel | bb-2121 | Approved | Bluebird Bio Inc | Abecma | Japan | Multiple Myeloma | Bristol-Myers Squibb Kk | 2021-03-26 | Multiple Myeloma | Details |
| Teclistamab | JNJ-64007957; JNJ-64007959; JNJ-7957 | Approved | Genmab A/S, Janssen Global Services Llc | TECAYLI | United States | Multiple Myeloma | Janssen Biotech Inc | 2022-08-23 | Hematologic Diseases; Hematologic Neoplasms; Smoldering Multiple Myeloma; Multiple Myeloma | Details |
| Belantamab mafodotin | GSK-2857916; GSK2857916 | Approved | Glaxosmithkline Plc | BLENREP | EU | Multiple Myeloma | Glaxosmithkline (Ireland) Ltd | 2020-08-05 | Bone Marrow Neoplasms; Lymphoma, B-Cell; Immunoglobulin Light-chain Amyloidosis; Multiple Myeloma; Plasmablastic Lymphoma; Amyloidosis | Details |
| Ciltacabtagene autoleucel | JNJ-4528; LCAR-B38M; JNJ-68284528 | Approved | Nanjing Legend Biotechnology Co Ltd | Carvykti | Japan | Multiple Myeloma | Nanjing Legend Biotechnology Co Ltd | 2022-02-28 | Multiple Myeloma | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| HBI-0101 | HBI-0101 | Phase 1 Clinical | Hadassah Medical Organization | Details | |
| Anti-BCMA CAR T cell therapy (Wuhan Bio-Raid Biotechnology) | Clinical | Wuhan Bio-Raid Biotechnology | Hematologic Neoplasms | Details | |
| BCMA CAR-T cell therapy (Hebei Senlang Biotechnology) | Clinical | Hebei Senlang Biological Technology Co Ltd | Multiple Myeloma | Details | |
| Recombinant humanized anti-BCMA/CD3 bispecific antibody(New Time Pharmaceutical) | Phase 1 Clinical | Shandong New Time Pharmaceutical Co Ltd | Multiple Myeloma | Details | |
| BCMA-NKE | BCMA-NKE | Phase 1 Clinical | Bristol-Myers Squibb Company | Multiple Myeloma | Details |
| HY-027 | HY-027 | Phase 1 Clinical | Multiple Myeloma | Details | |
| Anti-BCMA CAR T-cell therapy (Huazhong University of Science and Technology) | Clinical | Huazhong University Of Science And Technology | Multiple Myeloma | Details | |
| Anti-BCMA anti-CD38 bispecific chimeric antigen receptor T cell therapy (Shengyan Pharmaceutical Technology) | Phase 1 Clinical | Wuhan Union Hospital, Shengyan Pharmaceutical Technology | Multiple Myeloma | Details | |
| Ispectamab debotansine | CC-99712; BMS-986352; SP-8919 | Phase 1 Clinical | Celgene Corp | Multiple Myeloma | Details |
| MCM-998 | MCM-998; LXG-250 | Phase 1 Clinical | Novartis Pharma Ag | Multiple Myeloma | Details |
| BCMA-UCART cell therapy (Shanghai Bioray Laboratory) | Clinical | Multiple Myeloma | Details | ||
| BCMA-PD1 CAR T cell therapy (General Hospital of the People's Liberation Army) | Phase 2 Clinical | People'S Liberation Army General Hospital Military Service | Multiple Myeloma | Details | |
| Anti BCMA CART cell therapy (Shanghai YaKe Biotechnology) | Phase 1 Clinical | Shanghai YaKe Biotechnology Co Ltd | Multiple Myeloma | Details | |
| Anti BCMA chimeric antigen receptor T cell therapy (Chongqing Precision Biotech) | Phase 2 Clinical | Chongqing Precision Biotechnology Co Ltd | Multiple Myeloma | Details | |
| JWCAR129 | JWCAR129; JWCAR-129 | Phase 1 Clinical | Suzhou Yaomingjunuo Biotechnology Co Ltd | Multiple Myeloma | Details |
| GR-1803 | GR-1803 | Phase 1 Clinical | Chongqing Zhixiang Jintai Biopharmaceutical Co Ltd, Zhixiang (Shanghai) Pharmaceutical Technology Co Ltd | Multiple Myeloma | Details |
| Anti-BCMA CAR-T cell therapy (PersonGen Biomedicine) | Persongen Biotherapeutics | Details | |||
| C-4-29 | Phase 1 Clinical | Chongqing Precision Biotechnology Co Ltd | Carcinoma, Renal Cell; Multiple Myeloma | Details | |
| BCMA-targeted universal LCAR-BCX cell therapy (Nanjing Legend Biotech) | LCAR-BCX | Phase 1 Clinical | Multiple Myeloma | Details | |
| CXCR4 modified anti-BCMA CAR T cell therapy (Sichuan University) | Phase 1 Clinical | Sichuan University | Multiple Myeloma | Details | |
| EMB-06 | EMB-06; EMB06 | Phase 2 Clinical | Shanghai Epimab Biotherapeutics, Inc | Multiple Myeloma | Details |
| Anti-BCMA CAR-NK Cell Therapy (Sichuan Kelun-Biotech) | Sichuan Kelun-Biotech Biopharmaceutical Co Ltd | Details | |||
| BCMA CAR-T Cell Therapy (Shenzhen University General Hospital) | Shenzhen University General Hospital | Details | |||
| CAR-BCMA(Sheba Medical Center) | Phase 2 Clinical | Sheba Medical Center, Israel | Multiple Myeloma | Details | |
| MEDI-2228 | MEDI-2228 | Medimmune Llc | Details | ||
| ACLX-001 | ACLX-001 | Arcellx Inc | Details | ||
| BCMA/CD19 CAR-T cell therapy (The First Affiliated Hospital of Nanchang University) | The First Affiliated Hospital Of Nanchang University | Details | |||
| Alnuctamab | CC-93269; EM-901 | Celgene Corp | Details | ||
| BCMA CAR-T cell therapy (Chongqing Precision Biotech) | Chongqing Precision Biotechnology Co Ltd | Details | |||
| AMG-224 | AMG-224 | Amgen Inc | Details | ||
| PBCAR-269A | PBCAR-269A | Precision Biosciences Inc | Details | ||
| OriC-321 | OriC-321; Ori-C-321 | Phase 1 Clinical | Zhejiang University | Multiple Myeloma | Details |
| ACTR 087/SEA BCMA combination therapy | Phase 1 Clinical | Unum Therapeutics Inc | Multiple Myeloma | Details | |
| Orvacabtagene autoleucel | MCARH-171; ET-140; FCARH-143; ET140-CAR; JCARH-125 | Phase 2 Clinical | Multiple Myeloma | Details | |
| REGN-5459 | REGN-5459 | Phase 2 Clinical | Regeneron Pharmaceuticals Inc | Multiple Myeloma; Renal Insufficiency, Chronic | Details |
| Anti-CD19+/BCMA CAR-T cells (Hrain Biotechnology) | Phase 1 Clinical | Hrain Biotechnology Co Ltd | POEMS Syndrome | Details | |
| CART-BCMA | MTV-273; CART-BCMA | Phase 1 Clinical | University Of Pennsylvania | Multiple Myeloma | Details |
| Azintuxizumab | TNB-383B; ABBV-383 | Phase 2 Clinical | Teneobio Inc, Abbvie Inc | Multiple Myeloma | Details |
| Autologous BCMA-directed CAR T-cell therapy (The First Affiliated Hospital of Soochow University) | Phase 3 Clinical | The First Affiliated Hospital Of Soochow University | Leukemia; Multiple Myeloma | Details | |
| SEA-BCMA | SEA-BCMA; SGN-BCMA | Phase 1 Clinical | Seattle Genetics Inc | Multiple Myeloma | Details |
| CD19/BCMA-targeted CAR-T Cell Therapy (Zhejiang University) | Phase 1 Clinical | Zhejiang University | Nephritis; Sjogren's Syndrome; Scleroderma, Systemic; Autoimmune Diseases; Multiple Myeloma; Lupus Nephritis; Lupus Erythematosus, Systemic; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin | Details | |
| BCMA Targeted CAR-T Cell Therapy (Yake Biotechnology) | CBG-002 CAR-T | Phase 1 Clinical | Shanghai YaKe Biotechnology Co Ltd | Multiple Myeloma | Details |
| Anti-BCMA CAR-T cell therapy (Xinqiao Hospital) | Phase 1 Clinical | Multiple Myeloma | Details | ||
| Humanized CART Directed Against BCMA | ARI-0002h | Phase 2 Clinical | Instituto De Salud Carlos Iii | Multiple Myeloma | Details |
| MCARH-125 | MCARH-125 | Phase 1 Clinical | Memorial Sloan Kettering Cancer Center | Multiple Myeloma | Details |
| LCAR-B4822M | LCAR-B4822M | Phase 1 Clinical | Genscript Biotech Corp | Multiple Myeloma | Details |
| HDP-101 | HDP-101; HDP101-ATAC | Phase 2 Clinical | Heidelberg | Paraproteinemias; Multiple Myeloma | Details |
| BCMA-CS1 cCAR T cell therapy (iCell Gene Therapeutics) | Phase 1 Clinical | Multiple Myeloma | Details | ||
| LUCAR-B68 cells Therapy(Nanjing Legend Biotech Co) | Phase 1 Clinical | Nanjing Legend Biotechnology Co Ltd | Multiple Myeloma | Details | |
| FT-576 | FT-576 | Phase 1 Clinical | University Of Minnesota, Fate Therapeutics Inc | Bone Marrow Neoplasms; Multiple Myeloma | Details |
| BCMA CAR-NK 92 cell therapy (Asclepius Technology Company Group) | Phase 2 Clinical | Asclepius Technology Company Group | Multiple Myeloma | Details | |
| CC-98633 | CC-98633 | Phase 1 Clinical | Celgene Corp | Multiple Myeloma | Details |
| Motacabtagene lurevgedleucel | CTX-120 | Phase 1 Clinical | Crispr Therapeutics Ag | Multiple Myeloma | Details |
| Anti-BCMA/CD19 CAR-T Therapy(University College London) | Phase 1 Clinical | University College London | Multiple Myeloma | Details | |
| AUTO-2 | AUTO-2; SUB-96123 | Phase 1 Clinical | Autolus | Multiple Myeloma | Details |
| Pavurutamab | AMG-701 | Phase 1 Clinical | Amgen Inc | Multiple Myeloma | Details |
| PHE-885 | PHE-885 | Phase 2 Clinical | Novartis Pharma Ag | Hematologic Neoplasms; Multiple Myeloma | Details |
| CM-336(Connaught Biomedical Technology) | CM-336 | Phase 2 Clinical | Keymed Biosciences Co Ltd | Multiple Myeloma | Details |
| BCMA-CD19 cCAR T cell therapy (iCell Gene Therapeutics) | Phase 1 Clinical | Icell Gene Therapeutics (Int'L) Ltd | Multiple Myeloma; Lupus Erythematosus, Systemic | Details | |
| Anti-BCMA chimeric antigen receptor T cell therapy (Cartesian) | Descartes-08 | Phase 2 Clinical | Cartesian Therapeutics Inc | Myasthenia Gravis; Multiple Myeloma | Details |
| Anti-BCMA CAR T-cell therapy (Actavis/Eugia Pharma) | Phase 1 Clinical | Eugia Pharma Specialities Ltd, Actavis Inc | Multiple Myeloma | Details | |
| F-182112 | F-182112; F182112 | Phase 1 Clinical | Shandong New Time Pharmaceutical Co Ltd | Multiple Myeloma | Details |
| WVT-078(Novartis Pharma) | WVT-078 | Phase 1 Clinical | Novartis Pharma Ag | Multiple Myeloma | Details |
| Anti BCMA CAR T cell therapy (Shanghai Hrain Biotechnology) | BCMA-CART | Phase 2 Clinical | Hrain Biotechnology Co Ltd | Multiple Myeloma | Details |
| Autologous anti-BCMA/GPRC5D CAR-T cell therapy (Xuzhou Medical University) | Phase 2 Clinical | Xuzhou Medical University (Xzmu) | Multiple Myeloma | Details | |
| GC-012F | GC-012F | Phase 2 Clinical | Gracell Biotechnologies (Shanghai) Co Ltd | Multiple Myeloma; Lymphoma, Non-Hodgkin | Details |
| Descartes-11 | Descartes-11; Descartes-011 | Phase 2 Clinical | Cartesian Therapeutics Inc | Multiple Myeloma | Details |
| Anti-BCMA CAR T-cell therapy (Arcellx) | CART-ddBCMA | Phase 2 Clinical | Arcellx Inc | Multiple Myeloma | Details |
| IBI-346 | IBI-346 | Phase 1 Clinical | Innovent Biologics(Suzhou) Co Ltd | Multiple Myeloma | Details |
| C-CAR088 | C-CAR088 | Phase 2 Clinical | Cellular Biomedicine (Shanghai) Co Ltd | Multiple Myeloma | Details |
| Elranatamab | PF-06863135 | Phase 3 Clinical | Pfizer Pharmaceuticals Ltd (China) | Bone Marrow Neoplasms; Multiple Myeloma | Details |
| ALLO-605 | ALLO-605; ALLO605 | Phase 2 Clinical | Allogene Therapeutics Inc | Multiple Myeloma | Details |
| Linvoseltamab | REGN-5458 | Phase 2 Clinical | Regeneron Pharmaceuticals Inc | Multiple Myeloma; Renal Insufficiency, Chronic | Details |
| ALLO-715 | ALLO-715 | Phase 1 Clinical | Allogene Therapeutics Inc, Cellectis Sa | Multiple Myeloma | Details |
| Pacanalotamab | AMG-420; BI-836909 | Phase 1 Clinical | Micromet Inc | Multiple Myeloma | Details |
| bb-21217 | bb-21217 | Phase 1 Clinical | Bluebird Bio Inc, Bristol-Myers Squibb Company | Multiple Myeloma | Details |
| BCMA CAR-T Cells (Pregene) | PRG-1801 | Phase 1 Clinical | Shenzhen Prekin Biopharmaceutical Co Ltd | Multiple Myeloma | Details |
| BCMA TriTAC | HPN-217 | Phase 1 Clinical | Harpoon Therapeutics, Abbvie Inc | Multiple Myeloma | Details |
This web search service is supported by Google Inc.
アクロバイオシステムズの公式アカウント
A-Z
